Vinblastine (Velban) — Clinical FAQs

Question 1

What is Vinblastine FDA-approved to treat?

Accepted Answer

Vinblastine is FDA-approved for the following oncology indications: 1. Hodgkin lymphoma (component of ABVD regimen) 2. Non-Hodgkin lymphoma 3. Testicular carcinoma (non-seminomatous germ cell tumors) 4. Breast carcinoma (refractory) 5. Choriocarcinoma (and 4 additional indications).

Question 2

How does Vinblastine work (mechanism of action)?

Accepted Answer

Vinblastine is a naturally occurring vinca alkaloid derived from the Madagascar periwinkle plant (Catharanthus roseus) that exerts cytotoxic activity by binding specifically to tubulin dimers and inhibiting their polymerization into microtubules. This disrupts the mitotic spindle apparatus, arresting cells in metaphase (M phase) by preventing chromosome segregation. At higher concentrations, vinblastine can also disrupt interphase microtubule networks involved in axonal transport and intracellular vesicle trafficking. Unlike vincristine, vinblastine causes more pronounced myelosuppression and relatively less neurotoxicity, reflecting differential tissue distribution and binding affinities.

Question 3

How is Vinblastine administered?

Accepted Answer

Vinblastine is administered Intravenous (IV). Vinblastine is administered EXCLUSIVELY by the intravenous route — intrathecal administration is FATAL and must be prevented by dispensing in a minibag (NOT a syringe) clearly labeled "For Intravenous Use Only — Fatal if Given Intrathecally.

Question 4

What are the most common side effects of Vinblastine?

Accepted Answer

The most commonly reported side effects of Vinblastine (≥10% incidence) include: Myelosuppression: leukopenia/neutropenia (dose-limiting; nadir day 5–10, recovery by day 14–21), Thrombocytopenia and anemia (less common than leukopenia), Nausea and vomiting (mild to moderate), Constipation and abdominal cramping (neurotoxic ileus), Alopecia (mild to moderate) and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Vinblastine have a black box warning?

Accepted Answer

Yes. Vinblastine carries FDA black box warning(s) regarding: 1. Fatal if given intrathecally: Vinblastine is for intravenous use only. Intrathecal administration causes ascending paralysis and death. Dispense vinblastine in a minibag, NEVER in a syringe, to prevent inadvertent intrathecal injection. Syringes containing vinblastine must be labeled: "WARNING — FOR IV USE ONLY — FATAL IF GIVEN INTRATHECALLY." 2. Myelosuppression: Dose-limiting leukopenia can lead to life-threatening infections. Reduce dose or delay therapy for significant neutropenia; avoid use in patients with severe myelosuppression.

Question 6

Is Vinblastine safe during pregnancy?

Accepted Answer

Vinblastine pregnancy safety: Category D — Vinblastine causes fetal harm based on its mechanism of action and animal studies demonstrating teratogenicity and embryotoxicity. Women of childbearing potential must use effective contraception during therapy. Males should be counseled on sperm cryopreservation due to risk of infertility (azoospermia).. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Vinblastine — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms